Management of Extensive Proximal (Iliofemoral) Deep Vein Thrombosis

Immediate Anticoagulation Strategy

The American College of Radiology recommends initiating therapeutic anticoagulation without delay in all adults with extensive iliofemoral DVT, using a DOAC or low‑molecular‑weight heparin (LMWH) as first‑line agents; catheter‑directed thrombolysis (CDT) should be reserved for patients < 65 years with severe symptoms and low bleeding risk. [@1]
The American College of Chest Physicians advises that DOACs (rivaroxaban 15 mg bid for 21 days then 20 mg daily; apixaban 10 mg bid for 7 days then 5 mg daily) are preferred first‑line because they require no parenteral bridge, have comparable efficacy to warfarin, lower bleeding risk, and enable outpatient care (Class I, Level A). [@3]
The American College of Chest Physicians recommends LMWH (e.g., enoxaparin 1 mg/kg subcutaneously q12 h) or fondaparinux rather than unfractionated heparin for initial treatment of iliofemoral DVT (Class I, Level A). [@3]

Anticoagulation alone remains the standard therapy for most iliofemoral DVT; the ATTRACT randomized trial showed no reduction in post‑thrombotic syndrome at 2 years with CDT (Class IIa, Level A). [@1]
Indications for CDT (American College of Radiology):
- Limb‑threatening ischemia such as phlegmasia cerulea dolens. [@1]
- Select young patients (< 65 yr) with acute (< 14 days) iliofemoral DVT, moderate‑to‑severe symptoms, low bleeding risk, and good functional status. [@1]
Contraindications (American College of Radiology):
- Symptom duration > 14 days.
- Elderly patients or those with high bleeding risk.
- Isolated femoropopliteal DVT without iliac involvement.
- Use of CDT for routine management of iliofemoral DVT. [@1]
When CDT is performed, the American Heart Association/ACC advises low‑dose catheter‑directed rtPA (≈0.01 mg/kg) rather than systemic thrombolysis, which carries a 14 % major‑bleeding risk (Class IIb, Level B). [@4]

The American College of Radiology recommends suspecting May‑Thurner syndrome in young patients presenting with left‑sided iliofemoral DVT and obtaining cross‑sectional imaging (CTA or MRA) to identify iliac vein compression. [@1]
If an obstructive lesion is confirmed, combined anticoagulation and iliac‑vein stenting is advised because recurrent VTE is more frequent with anticoagulation alone. [@2]

The American Heart Association/ACC recommends against routine IVC‑filter placement in patients who can receive anticoagulation; although filters reduce symptomatic pulmonary embolism (6.2 % vs 15.1 % at 8 years), they increase recurrent DVT and do not improve mortality (Class III, Harm). [@4]
IVC filters should be placed only when there is an absolute contraindication to anticoagulation or active bleeding, and anticoagulation must be resumed once the contraindication resolves. [@4]

Provoked DVT (e.g., surgery, transient risk factor): a fixed 3‑month anticoagulation course is sufficient (Class I, Level A). [@3]
Unprovoked DVT: minimum 3 months, followed by reassessment; indefinite therapy is suggested for patients with low‑to‑moderate bleeding risk, whereas therapy should stop at 3 months if bleeding risk is high (Class IIa, Level A). [@3]
Cancer‑associated DVT: extend anticoagulation for at least 3–6 months and continue while cancer is active; LMWH is preferred over warfarin or DOACs (Class I, Level A). [@3]

The American College of Radiology states that most patients with iliofemoral DVT can be safely managed as outpatients with close follow‑up; hospitalization is reserved for limb‑threatening ischemia, severe symptoms requiring CDT, significant comorbidities or high bleeding risk, or inability to adhere to outpatient anticoagulation. [@1]

Routine compression stockings are not recommended for prevention of post‑thrombotic syndrome after iliofemoral DVT, although they may be used on an individual basis for symptom relief (Class III, Harm). [@2]

Do not delay anticoagulation while awaiting imaging in patients with high clinical suspicion; start empiric parenteral anticoagulation promptly (Class I, Level A). [@3]
Avoid systemic thrombolysis; transfer patients to centers capable of catheter‑directed therapy because systemic thrombolysis carries a 14 % major‑bleeding risk (Class III, Harm). [@4]
Do not discontinue anticoagulation prematurely after unprovoked DVT, as this markedly increases recurrence risk (Class I, Level A). [@3]
Do not place IVC filters routinely; they increase recurrent DVT without mortality benefit (Class III, Harm). [@4]